• Company
    • Synthetic Biology
    • Our Platform
    • Operating Units & Divisions
    • Subsidiaries
    • Management
    • Board of Directors
    • Our Commitment
  • Technologies
    • UltraVector®
    • RheoSwitch®
    • Cell Systems Informatics
    • Protein Engineering
    • AttSite™ Recombinases
    • LEAP®
    • Antibody Discovery
    • Neurospora & Agaricus Platforms
    • Endometrial Regenerative Cells
    • ActoBiotics®
    • Porcine Research Models
    • BeyondBio™
    • Scientific Literature
  • Markets
    • Health
    • Food
    • Energy
    • Environment
    • Consumer
  • Collaborations
    • Exclusive Channel Collaborations
    • Joint Ventures
    • Private Companies
    • Office of Academic Alliances & Technology Licensing
    • Partnering Opportunities
  • Investors
    • Overview
    • Press Releases
    • Collaborator News
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Events/Conferences
    • Investors Packet
    • FAQ
    • Information Request
    • IRS Form 8937
  • Careers
  • Contact
  • Contact
Search
At Intrexon we are committed to building…
A Better World Through Better DNA™
Whether engineering novel therapies in health, delivering unique solutions to address global energy demand, enabling unparalleled productivity advancements in food, or developing innovative applications in the consumer and environment sectors, we are working diligently today to create a better tomorrow.
Engineering novel solutions in HEALTH to achieve improved outcomes
Building a sustainable path to produce healthy, affordable FOOD
Utilizing a proprietary bioconversion platform for efficient ENERGY products
Developing innovative solutions for the ENVIRONMENT
Designing bio based CONSUMER solutions
At Intrexon we are committed to building…
A Better World Through Better DNA™

IN THE NEWS

2/13/2017 Lt. Gen. (Ret.) Thomas P. Bostick, Head of Intrexon’s Environment Sector, Elected to National Academy of Engineering
1/31/2017 ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing "Point-of-Care" Approach
1/26/2017 Exemplar Genetics Awarded Subcontract to Advance New Therapeutic Models for Sickle Cell Disease
1/24/2017 Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform
1/23/2017 Oxitec and GBIT announce launch of Friendly™ Aedes Project in India
1/19/2017 AquaBounty Announces Completion of NASDAQ Listing and Equity Subscription from Intrexon
1/12/2017 Intrexon Announces “When-Issued” Trading of AquaBounty Technologies In Connection With Special Stock Dividend of Shares

ENGINEERING SOLUTIONS

 Oxitec's Vector Control Solution: A Paradigm Shift
in Mosquito Control
 Forging a New Frontier in Cellular Therapeutics:
Oral ActoBiotics® Biopharmaceuticals
 Precise Gene Expression:
Proprietary RheoSwitch® Technology Platform
  • Company
    • Synthetic Biology
    • Our Platform
    • Operating Units & Divisions
    • Subsidiaries
    • Management
    • Board of Directors
    • Our Commitment
  • Technologies
    • UltraVector®
    • RheoSwitch®
    • Cell Systems Informatics
    • Protein Engineering
    • AttSite™ Recombinases
    • LEAP®
    • Antibody Discovery
    • Neurospora & Agaricus Platforms
    • Endometrial Regenerative Cells
    • ActoBiotics®
    • Porcine Research Models
    • BeyondBio™
    • Scientific Literature
  • Markets
    • Health
    • Food
    • Energy
    • Environment
    • Consumer
  • Collaborations
    • Exclusive Channel Collaborations
    • Joint Ventures
    • Private Companies
    • Intrexon Institute for Biomolecular Research
    • Partnering Opportunities
  • Investors
    • Overview
    • Press Releases
    • Collaborator News
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Events/Conferences
    • Investors Packet
    • FAQ
    • Information Request
    • IRS Form 8937
  • Careers
  • Contact
 
Legal Notices
© 2017 Intrexon
Web Solution by IDD, Inc.